SCY-078 (formerly MK-3118) is a novel orally active inhibitor of fungal β-(1,3)-glucan synthase (GS). SCY-078 is a derivative of enfumafungin and is structurally distinct from the echinocandin class of antifungal agents. We evaluated the activity of this compound against wild-type (WT) and echinocandin-resistant isolates containing mutations in the genes of spp. Against 36 spp. mutants tested, 30 (83.3%) were non-WT to 1 or more echinocandins, and only 9 (25.0%) were non-WT (MIC, >WT-upper limit) to SCY-078. Among isolates carrying alterations, 84.0% were non-WT to the echinocandins versus only 24.0% for SCY-078. In contrast to the echinocandin comparators, the activity of SCY-078 was minimally affected by the presence of mutations, suggesting that this agent is useful in the treatment of infections due to echinocandin-resistant strains.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527608PMC
http://dx.doi.org/10.1128/AAC.00161-17DOI Listing

Publication Analysis

Top Keywords

wild-type echinocandin-resistant
8
echinocandin-resistant strains
8
non-wt echinocandins
8
scy-078
6
differential activity
4
activity oral
4
oral glucan
4
glucan synthase
4
synthase inhibitor
4
inhibitor scy-078
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!